Development of tinzaparin: A heparinase-digested low-molecular-weight heparin

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 3 SUPPL. 1, 2000, Pages 23-29

  Hedner, U ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Development; Thrombo prophylaxis; Tinzaparin; Treatment of deep vein thrombosis

Indexed keywords

ARDEPARIN; CERTOPARIN; CY 216A; CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARIN LYASE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; BLEEDING; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME DEGRADATION; GENERAL SURGERY; HUMAN; META ANALYSIS; MOLECULAR WEIGHT; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROPHYLAXIS; VEIN THROMBOSIS;

ANIMALS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN LYASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOSIS;

EID: 0033816137     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis
2. Heparin as a prophylaxis against thrombosis
3. Studies on fractionated heparin
4. The molecular-weight range of mucosal-heparin preparations
5. The measurement of heparin. A method based on the potentiation of anti-factor Xa
6. Plasma heparin: A unique, practical, submicrogram-sensitive assay
7. The inhibition of blood clotting: An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombin
8. Highly purified antithrombin 3 with heparin co-factor activity prepared by disc electrophoresis
9. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor
10. Biological properties of the naturally occurring plasma inhibitor to activated factor X
11. The purification and mechanism of action of human antithrombin-heparin cofactor
12. Actions and interactions of antithrombin and heparin
13. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders
14. Chemistry of heparin and low molecular weight heparin
15. Biochemical and pharmacologic inequivalence of low molecular weight heparins
16. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin enoxaparin
17. No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin
18. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers
19. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers
20. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization
21. Comment on two papers by Dr. J. Fareed
22. The effect of low molecular weight heparin on experimental thrombosis and haemostasis - The influence of production method
23. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin
24. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats
25. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats
26. Placental transport of heparin
27. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy
28. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine
29. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group
30. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
31. Comparison of the thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement
32. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo
33. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
34. Comparison of the thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement
35. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin